REGENXBIO, Inc
REGENXBIO is leading the effort to translate the latest gene delivery research into therapeutic applications for diseases where there is serious unmet need. We are developing novel therapeutics and research tools based on rAAV (recombinant adeno-associated) vectors. Our NAV® Technology offers a platform for safer, highly efficient and specific expression of biologics with therapeutic effect.
REGENXBIO’s NAV Technology, based on decades of research, is moving from the laboratory to the clinic and we believe that our technology will become one of the cornerstones of the biotech industry .
